310 related articles for article (PubMed ID: 25770156)
21. Functional screening reveals HORMAD1-driven gene dependencies associated with translesion synthesis and replication stress tolerance.
Tarantino D; Walker C; Weekes D; Pemberton H; Davidson K; Torga G; Frankum J; Mendes-Pereira AM; Prince C; Ferro R; Brough R; Pettitt SJ; Lord CJ; Grigoriadis A; Nj Tutt A
Oncogene; 2022 Aug; 41(32):3969-3977. PubMed ID: 35768547
[TBL] [Abstract][Full Text] [Related]
22. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
23. BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer.
Tazzite A; Jouhadi H; Benider A; Nadifi S
Curr Drug Targets; 2020; 21(10):962-973. PubMed ID: 32013831
[TBL] [Abstract][Full Text] [Related]
24. Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.
Jin J; Zhang W; Ji W; Yang F; Guan X
Cancer Biol Ther; 2017 Jun; 18(6):369-378. PubMed ID: 28494179
[TBL] [Abstract][Full Text] [Related]
25. Ectopically Expressed Meiosis-Specific Cancer Testis Antigen HORMAD1 Promotes Genomic Instability in Squamous Cell Carcinomas.
Gantchev J; Messina-Pacheco J; Martínez Villarreal A; Ramchatesingh B; Lefrançois P; Xie P; Amar L; Xu HH; Raveendra K; Sikorski D; Guerra Ordaz DJ; Gill RPK; Lambert M; Litvinov IV
Cells; 2023 Jun; 12(12):. PubMed ID: 37371097
[TBL] [Abstract][Full Text] [Related]
26. The Cancer/Testes (CT) Antigen HORMAD1 promotes Homologous Recombinational DNA Repair and Radioresistance in Lung adenocarcinoma cells.
Gao Y; Kardos J; Yang Y; Tamir TY; Mutter-Rottmayer E; Weissman B; Major MB; Kim WY; Vaziri C
Sci Rep; 2018 Oct; 8(1):15304. PubMed ID: 30333500
[TBL] [Abstract][Full Text] [Related]
27. The VEGF receptor neuropilin 2 promotes homologous recombination by stimulating YAP/TAZ-mediated Rad51 expression.
Elaimy AL; Amante JJ; Zhu LJ; Wang M; Walmsley CS; FitzGerald TJ; Goel HL; Mercurio AM
Proc Natl Acad Sci U S A; 2019 Jul; 116(28):14174-14180. PubMed ID: 31235595
[TBL] [Abstract][Full Text] [Related]
28. Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies.
Ma D; Jiang YZ; Xiao Y; Xie MD; Zhao S; Jin X; Xu XE; Shao ZM
Cancer; 2020 Jul; 126(14):3209-3218. PubMed ID: 32383785
[TBL] [Abstract][Full Text] [Related]
29. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
Tutt A; Tovey H; Cheang MCU; Kernaghan S; Kilburn L; Gazinska P; Owen J; Abraham J; Barrett S; Barrett-Lee P; Brown R; Chan S; Dowsett M; Flanagan JM; Fox L; Grigoriadis A; Gutin A; Harper-Wynne C; Hatton MQ; Hoadley KA; Parikh J; Parker P; Perou CM; Roylance R; Shah V; Shaw A; Smith IE; Timms KM; Wardley AM; Wilson G; Gillett C; Lanchbury JS; Ashworth A; Rahman N; Harries M; Ellis P; Pinder SE; Bliss JM
Nat Med; 2018 May; 24(5):628-637. PubMed ID: 29713086
[TBL] [Abstract][Full Text] [Related]
30. BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.
Domagala P; Hybiak J; Cybulski C; Lubinski J
Int J Cancer; 2017 Apr; 140(7):1545-1550. PubMed ID: 27943282
[TBL] [Abstract][Full Text] [Related]
31. Optimizing chemotherapy in triple-negative breast cancer: the role of platinum.
Telli M
Am Soc Clin Oncol Educ Book; 2014; ():e37-42. PubMed ID: 24857126
[TBL] [Abstract][Full Text] [Related]
32. HORMAD1 Is a Negative Prognostic Indicator in Lung Adenocarcinoma and Specifies Resistance to Oxidative and Genotoxic Stress.
Nichols BA; Oswald NW; McMillan EA; McGlynn K; Yan J; Kim MS; Saha J; Mallipeddi PL; LaDuke SA; Villalobos PA; Rodriguez-Canales J; Wistuba II; Posner BA; Davis AJ; Minna JD; MacMillan JB; Whitehurst AW
Cancer Res; 2018 Nov; 78(21):6196-6208. PubMed ID: 30185546
[TBL] [Abstract][Full Text] [Related]
33. GLI1-targeting drugs induce replication stress and homologous recombination deficiency and synergize with PARP-targeted therapies in triple negative breast cancer cells.
Mani C; Tripathi K; Omy TR; Reedy M; Manne U; Palle K
Biochim Biophys Acta Mol Basis Dis; 2022 Feb; 1868(2):166300. PubMed ID: 34748904
[TBL] [Abstract][Full Text] [Related]
34. BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.
Severson TM; Peeters J; Majewski I; Michaut M; Bosma A; Schouten PC; Chin SF; Pereira B; Goldgraben MA; Bismeijer T; Kluin RJ; Muris JJ; Jirström K; Kerkhoven RM; Wessels L; Caldas C; Bernards R; Simon IM; Linn S
Mol Oncol; 2015 Oct; 9(8):1528-38. PubMed ID: 26004083
[TBL] [Abstract][Full Text] [Related]
35. Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).
Sharma P; Barlow WE; Godwin AK; Pathak H; Isakova K; Williams D; Timms KM; Hartman AR; Wenstrup RJ; Linden HM; Tripathy D; Hortobagyi GN; Hayes DF
Ann Oncol; 2018 Mar; 29(3):654-660. PubMed ID: 29293876
[TBL] [Abstract][Full Text] [Related]
36. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
Marzio A; Puccini J; Kwon Y; Maverakis NK; Arbini A; Sung P; Bar-Sagi D; Pagano M
Mol Cell; 2019 Jan; 73(2):224-237.e6. PubMed ID: 30554948
[TBL] [Abstract][Full Text] [Related]
37. Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.
Ueno T; Kitano S; Masuda N; Ikarashi D; Yamashita M; Chiba T; Kadoya T; Bando H; Yamanaka T; Ohtani S; Nagai S; Nakayama T; Takahashi M; Saji S; Aogi K; Velaga R; Kawaguchi K; Morita S; Haga H; Ohno S; Toi M
BMC Med; 2022 Apr; 20(1):136. PubMed ID: 35462552
[TBL] [Abstract][Full Text] [Related]
38. CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
Johnson SF; Cruz C; Greifenberg AK; Dust S; Stover DG; Chi D; Primack B; Cao S; Bernhardy AJ; Coulson R; Lazaro JB; Kochupurakkal B; Sun H; Unitt C; Moreau LA; Sarosiek KA; Scaltriti M; Juric D; Baselga J; Richardson AL; Rodig SJ; D'Andrea AD; Balmaña J; Johnson N; Geyer M; Serra V; Lim E; Shapiro GI
Cell Rep; 2016 Nov; 17(9):2367-2381. PubMed ID: 27880910
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients.
de Boo LW; Jóźwiak K; Joensuu H; Lindman H; Lauttia S; Opdam M; van Steenis C; Brugman W; Kluin RJC; Schouten PC; Kok M; Nederlof PM; Hauptmann M; Linn SC
Br J Cancer; 2022 Jun; 126(10):1401-1409. PubMed ID: 35124703
[TBL] [Abstract][Full Text] [Related]
40. Genomic and epigenomic
Menghi F; Banda K; Kumar P; Straub R; Dobrolecki L; Rodriguez IV; Yost SE; Chandok H; Radke MR; Somlo G; Yuan Y; Lewis MT; Swisher EM; Liu ET
Sci Transl Med; 2022 Jul; 14(652):eabn1926. PubMed ID: 35857626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]